Curalin supplement for patients with type 2 diabetes mellitus
Roni Weinberg Sibony(Rabin Medical Center), Itamar Raz(Hebrew University of Jerusalem), Aliza Rozenberg(Hebrew University of Jerusalem), Maya Ish‐Shalom(Tel Aviv University), Tali Ganz(Wolfson Medical Center), Uri Eliyahu(Ariel University), Julio Wainstein(Wolfson Medical Center), Ilan Yanuv(Hebrew University of Jerusalem)
Cited by 1
Related Papers
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
|The Lancet Diabetes & Endocrinology|2019|673
Overview of oxidative stress and inflammation in diabetes
|Journal of Diabetes|2024|216
Drug Therapies for Diabetes
|International Journal of Molecular Sciences|2023|99